The ER-, PR- and HER-2 positive rate was comparable in this TC-BC group and the BC alone group (84.7%, 68.4% and 14.6% vs. 82.6%, 67.0%, 14.8% respectively). The gene discussed is ERBB2; the disease is breast cancer.